(19)
(11) EP 3 610 887 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.01.2024 Bulletin 2024/04

(45) Mention of the grant of the patent:
15.11.2023 Bulletin 2023/46

(21) Application number: 19194676.3

(22) Date of filing: 14.02.2014
(51) International Patent Classification (IPC): 
A61K 39/002(2006.01)
C12N 15/00(2006.01)
 A61K 39/012(2006.01)
A61P 31/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/012; C07K 14/445; A61K 2039/53; A61K 2039/542; A61K 2039/55583; A61P 31/04; Y02A 50/30

(54)

COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERSTÄRKUNG VON IMMUNREAKTIONEN GEGENÜBER EIMERIA ODER ZUR BEGRENZUNG VON EIMERIA-INFEKTIONEN

COMPOSITIONS ET PROCÉDÉS POUR RENFORCER DES RÉPONSES IMMUNITAIRES VIS-À-VIS D'EIMERIA OU LIMITER UNE INFECTION PAR EIMERIA

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.02.2013 US 201361764681 P

(43) Date of publication of application:
19.02.2020 Bulletin 2020/08

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14751914.4 / 2956165

(73) Proprietors:
  • The Board of Trustees of the University of Arkansas
    Little Rock, AR 72207 (US)
  • The Texas A&M University System
    College Station, TX 77843-3369 (US)

(72) Inventors:
  • BARTA, John R.
    Guelph Ontario N1G 2W1 (CA)
  • BERGHMAN, Luc
    College Station, TX 77845 (US)
  • BIELKE, Lisa
    Fayetteville, AR 72703 (US)
  • HARGIS, Billy
    Fayetteville, AR 72764 (US)
  • SHIVARAMAIAH, Srichaitanya
    560102 Bangalore (IN)
  • FAULKNER, Olivia B.
    Shawnee, KS 66203 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
WO-A2-2009/059298
 US-A1- 2012 282 291
   
  • LI JIANHUA ET AL: "Toxoplasma gondiirhomboid protein 1 (TgROM1) is a potential vaccine candidate against toxoplasmosis", VETERINARY PARASITOLOGY, vol. 184, no. 2, 2012, pages 154-160, XP028884817, ISSN: 0304-4017, DOI: 10.1016/J.VETPAR.2011.08.014
  • YINGLI LIU ET AL: "Protective immunity induced by a DNA vaccine encodingrhomboid against homologous challenge", PARASITOLOGY RESEARCH ; FOUNDED AS ZEITSCHRIFT FÜR PARASITENKUNDE, SPRINGER, BERLIN, DE, vol. 112, no. 1, 9 October 2012 (2012-10-09), pages 251-257, XP035159276, ISSN: 1432-1955, DOI: 10.1007/S00436-012-3132-2
  • F. BROSSIER ET AL: "A spatially localized rhomboid protease cleaves cell surface adhesins essential for invasion by Toxoplasma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 102, no. 11, 15 March 2005 (2005-03-15), pages 4146-4151, XP055293500, US ISSN: 0027-8424, DOI: 10.1073/pnas.0407918102
  • GENBANK: "rhomboid protease 5 [Toxoplasma gondii] - Protein - NCBI", , 16 March 2005 (2005-03-16), XP55654315, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/protein/a at84606 [retrieved on 2019-12-19]
  • UNIPROT: "NCLIV_001580 - RHOMBOID-like protein - Neospora caninum (strain Liverpool) - NCLIV_001580 gene & protein", , 3 May 2011 (2011-05-03), XP55654338, Retrieved from the Internet: URL:https://www.uniprot.org/uniprot/F0V7H9 [retrieved on 2019-12-19]
  • UNIPROT: "ROM4 - RHOMBOID-like protein - Eimeria tenella (Coccidian parasite) - ROM4 gene & protein", , 16 November 2011 (2011-11-16), XP055654340, Retrieved from the Internet: URL:https://www.uniprot.org/uniprot/G3LUI0 [retrieved on 2019-12-19]
  • WANG Q ET AL: "Protective immunity of recombinant Mycobacterium bovis BCG expressing rhomboid gene against Eimeria tenella challenge", VETERINARY PARASITOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 160, no. 3-4, 23 March 2009 (2009-03-23), pages 198-203, XP025995294, ISSN: 0304-4017, DOI: 10.1016/J.VETPAR.2008.11.006 [retrieved on 2008-11-13]
  • JIANHUA LI ET AL: "Efficacy ofrhomboid-like protein as a subunit vaccine in protective immunity against homologous challenge", PARASITOLOGY RESEARCH ; FOUNDED AS ZEITSCHRIFT FÜR PARASITENKUNDE, SPRINGER, BERLIN, DE, vol. 110, no. 3, 16 August 2011 (2011-08-16), pages 1139-1145, XP035016911, ISSN: 1432-1955, DOI: 10.1007/S00436-011-2603-1
  • Caoili Salvador Eugenio C.: "Benchmarking B-Cell Epitope Prediction for the Design of Peptide-Based Vaccines: Problems and Prospects", Journal of Biomedicine and Biotechnology, vol. 2010, 1 January 2010 (2010-01-01), pages 1-14, XP055779430, ISSN: 1110-7243, DOI: 10.1155/2010/910524 Retrieved from the Internet: URL:http://downloads.hindawi.com/journals/ bmri/2010/910524.pdf>
  • VERONESE ET AL.: "Loss of a Neutralizing Epitope by a Spontaneous Point Mutation in the V3 Loop of HIV-1 Isolated from an Infected Laboratory Worker*", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, 5 December 1993 (1993-12-05), pages 25894-25901, XP55979518, Retrieved from the Internet: URL:https://www.jbc.org/article/S0021-9258 (19)74471-8/pdf>
  • Ossendorp ET AL: "A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation", Immunity, vol. 5, 1 January 1996 (1996-01-01), pages 115-124, XP55979531,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).